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Background: Metastatic bone lesion is a common syndrome of many cancer diseases in an advanced state. The
major symptom is severe pain, spinal cord compression, and pathological fracture, associated with an obvious
morbidity. Common treatments including systemic application of bisphosphonate drugs aim on pain reduction and
on improving the quality of life of the patient. Particularly, patients with multiple metastatic lesions benefit from
bone-targeting therapeutic radiopharmaceuticals. Agents utilizing beta-emitting radionuclides in routine clinical
praxis are, for example, [89Sr]SrCl2 and [
153Sm]Sm-EDTMP. No-carrier-added (n.c.a.) 177Lu is remarkably suitable for an
application in this scope.
Methods: Five 1,4,7,10-tetraazacyclododecane N,N′,N′′,N′′-tetra-acetic acid (DOTA)- and DO2A-based bisphosphonates,
including monomeric and dimeric structures and one 1,4,7-triazacyclononane-1,4-diacetic acid (NO2A) derivative, were
synthesized and labelled with n.c.a. 177Lu. Radio-TLC and high-performance liquid chromatography (HPLC)
methods were successfully established for determining radiochemical yields and for quality control. Their
binding to hydroxyapatite was measured in vitro. Ex vivo biodistribution experiments and dynamic in vivo
single photon computed tomography (SPECT)/CT measurements were performed in healthy rats for 5 min
and 1 h periods. Data on %ID/g or standard uptake value (SUV) for femur, blood, and soft-tissue organs
were analyzed and compared with [177Lu]citrate.
Results: Radiolabelling yields for [177Lu]Lu-DOTA and [177Lu]Lu-NO2A monomeric bisphosphonate complexes
were >98 % within 15 min. The dimeric macrocyclic bisphosphonates showed a decelerated labelling kinetics,
reaching a plateau after 30 min of 60 to 90 % radiolabelling yields. All 177Lu-bisphosphonate complexes showed
exclusive accumulation in the skeleton. Blood clearance and renal elimination were fast. SUV data (all for 1 h p.i.)
in the femur ranged from 3.34 to 5.67. The bone/blood ratios were between 3.6 and 135.6, correspondingly. 177
Lu-bisphosphonate dimers showed a slightly higher bone accumulation (SUVfemur = 4.48 ± 0.38 for [
177Lu]
Lu-DO2A(PBP)2; SUVfemur = 5.41 ± 0.46 for [
177Lu]Lu-DOTA(MBP)2) but a slower blood clearance
(SUVblood = 1.25 ± 0.09 for [
177Lu]Lu-DO2A(PBP)2; SUVblood = 1.43 ± 0.32 for [
177Lu]Lu-DOTA(MBP)2).
Conclusions: Lu-complexes of macrocyclic bisphosphonates might become options for the therapy of
skeletal metastases in the near future, since they show high uptake in bone together with a very low
soft-tissue accumulation.
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Bone-seeking radiopharmaceuticals showed promising
results in the last decades both for diagnosis and therapy
[1]. The mechanism of the therapy effect is the synergy
of an enhanced accumulation of osteotropic agents on
the metastatic lesion and the energy deposit by particle
radiation (β−, inner conversion or α-particles). One of
the earliest therapeutic concepts was the administration
of 89SrCl2 as a calcium mimetic [2]. While
89Sr showed
unfavorable nuclear properties in terms of β-energy and
half-life (βmax = 1.5 MeV, t1/2 = 50 days) [3], new radio-
pharmaceuticals, like [153Sm]Sm-EDTMP were utilized.
More radionuclides are under consideration such as IC-
transforming 117mSn. Recently, α-emitting [223Ra]RaCl2
was introduced [1].
The potential of lanthanide radionuclides for bone
targeting was recognized early [4]. Skeletal 177Lu-images
were obtained with the Anger camera already in the
1960s [5]. The γ-photons of 113 keV (6.4 %) and
208 keV (11.4 %) [6] from the 177Lu decay are suitable
for single photon computed tomography (SPECT),
whereas today the focus of 177Lu-compounds is mainly
on the therapeutic benefit of the β−-emission. 177Lu-labelled
somatostatin analogues are successfully used in the treat-
ment of neuroendocrine tumors in the peptide receptor
radionuclide therapy (PRRT) [7]. The ideal nuclide proper-
ties of a half-life of 6.65 days and the maximum β-energy of
0.497 MeV [6] together with the carrier-free production
route make 177Lu an interesting candidate in the treatment
of skeletal metastases.
In the early times of radiopharmacy, it was discovered
already that the addition of chelating agents alters the
biological distribution of lanthanides from primary liver
uptake to almost exclusively bone accumulation [5]. “Bone
seeking” polycarboxy-polyphosphates like ethylenediamine
tetra(methylene phosphonic acid) (EDTMP) showed
promising first results [8, 9]. Due to their low kinetic
stability with lanthanide ions [10], a high EDTMP concen-
tration in the blood pool is necessary for a stable complex-
ation in vivo, which consequently creates a high amount
of ligand carrier [11]. As opposed to these open-chain
chelators, macrocyclic chelators like 1,4,7,10-tetraazacy-
clododecane N,N′,N″,N″-tetra-acetic acid (DOTA) show
a very strong thermodynamic and kinetic stability with
lanthanides [12, 13]. Even equimolar metal to DOTA
ratios guarantee for complexation and in vivo stability. Ini-
tial experiments with phosphonic acid derivatives (DOTP)
of DOTA complexed with 177Lu showed sufficient bone
accumulation and low uptake in soft tissue [14].
An ideal chelator-based positron emission tomog-
raphy (PET) nuclide is the generator-derived 68Ga.
Phosphonate-based macrocycles for 68Ga complex forma-
tion such as [68Ga]EDTMP and [68Ga]DOTP showed only
disappointing results in accumulating bone structures, incontrary to the 177Lu outcomes [15, 16]. The first com-
pound, which yielded excellent 68Ga-PET, was the DOTA-
based bisphosphonate BPAMD (for formula, see Chart 1)
[17, 18]. It is known that bisphosphonates in general have
a high affinity to calcified tissues and a very long biological
half-life in the skeleton [19]. [68Ga]BPAMD PET/CT
showed uptake values on disseminated bone metastases as
high as 18F-fluoride, sometimes even superior [20]. Re-
cently, the NOTA-derivative [68Ga]NO2APBP was identi-
fied to show even improved imaging quality [21]. In a
previous work, we investigated the potential of different
68Ga-labelled DOTA-conjugated bisphosphonates in an
animal model as PET imaging agents [22]. The logical step
is the following investigation in its potential as therapeutic
agents, when labelled with 177Lu. Nevertheless, we believe
that there still are various options to chemically modify
those chelate structures in order to maximize uptake on
bone metastases and to further reduce soft-tissue accumu-
lation. The current question, discussed in the present
paper, is whether analogue macrocyclic bisphosphonate li-
gands can directly be converted from 68Ga complexes to
177Lu analogues, i.e., retaining organ uptake and pharma-
cology profiles known from Ga(III) structures, or whether
an alternative ligand chemistry is needed to match the co-
ordination features of Lu(III).
Currently, several new macrocyclic bisphosphonates
are intensely discussed in the literature as candidates for
complex formation with 177Lu and 90Y and subsequent
“bone seeking” parameters, including hydroxy bispho-
sphonates [23] and phosphinates (Chart 1) [24]. In this
paper, the biodistribution and bone accumulation of vari-
ous macrocyclic bisphosphonates, including two dimeric
DOTA and one 1,4,7-triazacyclononane-1,4-diacetic acid
(NO2A) compounds (Chart 1), were studied in a healthy
rat model. The ligand synthesis, in particular the synthesis
of the new dimeric bisphosphonates DO2A(PBP)2 and
DOTA(MBP)2 as well as labelling with
177Lu and radio-
analytics, are reported. All the 177Lu species were investi-
gated in healthy rats in in vivo small animal SPECT and
ex vivo organ distribution (5 min to 1 h p.i.) studies and




Chemicals and solvents were commercially available in
analytical or high-performance liquid chromatography
(HPLC) grade and were purchased from Sigma-Aldrich
or Merck KGaA.
Analytics
Proton nuclear magnetic resonance (1H-NMR) spectra
were recorded on a Bruker 300, and 31P-NMR were
recorded on a Bruker 600. NMR shifts were referenced to
Chart 1 Structure of ligands discussed in this paper
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signal. Mass spectra were recorded on an Agilent Tech-
nologies 6130 Quadrupole LC/MS spectrometer with ESI
as ion source in positive or negative modes. TLC analyses
of the ligand and intermediates during their synthesis were
carried out with silica on aluminum foil (Merck).
Radio-TLC analyses of labelled compounds were
carried out with silica on aluminum foil (Merck) or
RP18 on alumina and a Canberra Packard Instant
Imager. Radio-HPLC was performed on a Hewlett
Packard Series 1100 with a Raytest (Radeberg, Germany)
Ramona radiodetector. Radioactivity of samples was
measured with an Aktivimeter Isomed 2010, MED
(Nuklear-Medizintechnik Dresden GmbH).
Radionuclides
No-carrier-added (n.c.a.) 177Lu was produced via the
176Yb-based neutron capture pathway provided by ITG
(Garching, Germany) as LuCl3 in 0.04 M HCl [25].
Synthesis of the dimeric bisphosphonates DOTA(MBP)2
and DO2A(PBP)2
1,4,7,10-tetraazacyclododecane-1,7-bis-tert.butyl diacetic
acid ester (tert.butyl-DO2A) [26], tetraethyl chloro-acetamidomethyl-bis(phosphonate) (1), tetraethyl{[(ethoxyhyd
rophosphoryl)methyl]methylene} bis(phosphonate) (4) and
the compounds DOTAMBP, DO3APBP, DOTAMEBP, and
NO2APBP were synthesized according to the published
literature [21, 27, 28].
DOTA(MBP)2 in ester form (2)
Tert.butyl-DO2A (200 mg, 0.5 mmol) was dissolved in
50 mL dry acetonitrile. Potassium carbonate (10 eq.,
5 mmol, 691 mg) was added, and the mixture was
heated to 40 °C. Tetraethyl chloro-acetamidomethyl-
bis(phosphonate) (1) (5 eq., 2.5 mmol, 948 mg) was
dissolved in 25 mL dry acetonitrile and added drop-
wise to the DO2A solution. The reaction mixture was
kept at 40 °C for 24 h under stirring and argon atmos-
phere. Activated charcoal was added, the solution was
filtered, and the solvent was removed under reduced
pressure. The crude product was purified by column
chromatography (silica phase using a solvent mixture
of NH4OH:MeOH:EA (1:4:15). Rf = 0.2–0.4) resulting
in a yellow oil (308.5 mg, 57 %). 1H-NMR (CDCl3,
300 MHz): δ 1.37 (m, 24H, CH2–CH3), 1.46 (s, 18H,
t-Bu), 2.6–3.0 (bs, 8H, cyclen– CH2–N), 3.1–3.5 (bs,
8H, cyclen– CH2–N), 3.5 (s, 8H, N–CH2–CO), 4.23
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31P-NMR (CDCl3, 162.05 MHz):
δ 7.78 (s, 2P). ESI-MS(+): cald 1086.49 obsd 1087.50
(M + H+), 1109.48 (M + Na+).
DOTA(MBP)2 (3)
The protected compound (2) (308.5 mg, 0.29 mmol) was
dissolved in dry dichloromethane, and trimethylsilylbro-
mide (20 eq., 6 mmol, 920 mg) was added at room
temperature under argon atmosphere. The reaction mix-
ture was stirred overnight, and volatiles were removed
under reduced pressure. The resulting red oil was
dissolved in methanol and stirred for 5 h until the
solvent was removed. The residue was kept under high
vacuum to remove volatiles until no change in weight
was observed. A subsequent 2:1 mixture of TFA/DCM
was added and the mixture was stirred overnight under
argon atmosphere. After removing the solvents under
reduced pressure, the crude compound was purified two
times by recrystallization from boiling water. The pre-
cipitating white solid was filtered, washed with etha-
nol, and dried in vacuum with a yield of 140 mg
(64 %). 1H-NMR (D2O/NaOD, 300 MHz): δ 2.84 (bs,
8H, cyclen–CH2–N), 2.92 (bs, 8H, cyclen–CH2–N),
3.37 (bs, 4H, N–CH2–CO), 3.64 (bs, 4H, N–CH2–CO),
4.38 (t, 2H, P–CH–P, 2JPH = 18.22 Hz).
31P-NMR (H2O/
NaOD, 162.05 MHz): δ 13.5. ESI-MS(–): cald 750.42 obsd
749.21 (M −H+), 374.10 (M − 2H+).
DO2A(PBP)2 in ester form (5)
To a solution of bisphosphonate (4) (2.4 g, 6 mmol) in
70 mL dry toluene, 601 mg tert.butyl-DO2A (0.25 eq.,
1.5 mmol) and 180 mg (1 eq., 6 mmol) paraformalde-
hyde were added. The reaction solution was stirred
under reflux for 24 h. The solvent was removed under
reduced pressure, and the residue was purified by column
chromatography (silica gel, NH4OH:MeOH:EA (1:4:15).
Rf = 0.2–0.3) resulting in 625 mg (35 %) of a pale yellow
oil. 31P-NMR (CDCl3, 162.05 MHz): δ 22.3 (m, 4P), 36.3
(m, 2P). ESI-MS(+): cald 1212.52 obsd 1213.51 (M+H+),
1236.53 (M+Na+).
DO2A(PBP)2 (6)
The protected bisphosphonate (5) (625 mg, 0.52 mmol)
was dissolved in 50 mL 6 M aqueous HCl and kept at a
temperature of 100 °C for 24 h. The solvent was evapo-
rated under reduced pressure, and the excess of HCl was
removed by repetitive co-evaporation from deionized
water. The crude product was passed over a strong
cation exchanger (Dowex 50, H+-form), and the aqueous
solution was dried by lyophilization. The white solid was
further purified by recrystallization from boiling water.
Precipitation was initiated by adding small volumes of
ethanol. The white solid (337 mg, 79 %) was filtered,
washed with ethanol, and dried in vacuum. 1H-NMR(D2O/NaOD, 300 MHz): δ 2.56 (m, 4H –CH2–CH), 3.1
(bs, 8H, cyclen–CH2–N), 3.3 (bs, 8H, cyclen–CH2–N),
3.4 (bs, 4H, N–CH2–P) 3.5 (m, 2H, P–CH–P) 3.7 (bs,
4H, N–CH2–CO).
31P-NMR (D2O/NaOD, 162.05 MHz):
δ 22.01 (s, 4P), 43.50 (s, 2P). ESI-MS(–): cald 820.08
obsd 819.04 (M −H+), 409.00 (M – 2H+).
Radiolabelling with n.c.a. 177Lu and quality control
Labelling of bisphosphonates with n.c.a. 177Lu was
performed in 0.1 M sodium acetate buffer at pH = 4, by
adding four volume equivalents of buffer to a solution of
177LuCl3 in 0.05 M HCl. A 10 M excess, based on
177Lu
concentration of bisphosphonate containing chelator,
was added, and the solution was kept on a thermo
shaker at 98 °C up to 30 min. [177Lu]citrate was
prepared by adding 100 μL 177LuCl3 in 0.05 M HCl to
100 μL of 0.25 M citrate buffer. Radiochemical yields
(RCY) were determined by radio-HPLC (Zorbax 300SB-
C18, 9.4 × 250 mm 5 μ, solvent: 100 mM tetraethylam-
monium phosphate pH = 2.24, 1 mL/min isocratic flow)
and were cross-checked by two radio-TLC methods
(silica, solvent: 0.1 M citrate buffer pH 4 and RP18 on
alumina, solvent: 100 mM tetraethylammonium phosphate
pH= 2.24 + 20 % ACN).
Animal studies
The experiments were realized corresponding to the
German animal welfare regulations and institutional
guidelines and with the permission of the local animal
research committee at the Landesdirektion, Dresden. All
experimental procedures are following the guidelines of the
European Convention for the Protection of Vertebrate Ani-
mals used for Experimental and other Scientific Purposes
(ETS No. 123). Male Wistar rats weighing 157.69 ± 17.10 g
(mean ± SD, N = 35) were purchased from Unilever
(HsdCpb:WU, Harlan Winkelmann, Borchen, Germany).
Anesthetization was initiated and maintained by desflurane,
and animals were put in the supine position and placed on
a heating pad to maintain body temperature. A needle
catheter was used for administration of the tracers in
the tail vein. A second catheter was introduced into
the right femoral artery for the extraction of blood
samples for metabolite analysis, which was routinely
done during SPECT/CT measurements.
Ex vivo biodistribution
The male Wistar rats received a short-term anesthetization
by desflurane inhalation. Mean activities of 2.36 ±
0.27 MBq/kg of the 177Lu-labelled tracers in isotonic
saline were injected in a volume of 0.5 mL in the tail vein,
with the following specific details: [177Lu]citrate: 2.56 ±
0.07 MBq/kg, 128.58 body weight (BW, g), n = 4 (g);
[177Lu]BPAMD: 2.33 ± 0.11 MBq/kg, 159.41 BW (g), n = 4
(g); [177Lu]BPAPD: 2.58 ± 0.24 MBq/kg, 156.38 BW
Scheme 1 Synthesis of DOTA(MBP)2. (i) K2CO3, acetonitrile, 40 °C (ii) 1. TMS-Br, DCM, RT; 2. MeOH; 3. TFA/DCM, RT
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BW (g), n = 4 (g); [177Lu]NO2APBP: 2.52 ± 0.25 MBq/kg,
173.82 BW (g), n = 4 (g); [177Lu]DOTA(MBP)2: 1.80 ±
0.10 MBq/kg, 181.64 BW (g), n = 4 (g); [177Lu]DO2A(PBP)2:
2.46 ± 0.15 MBq/kg, 150.60 BW (g), n = 4 (g). The com-
pounds [177Lu]DOTA(MBP)2, [
177Lu]BPPED, and [177Lu]B-
PAMD were further chosen for a biodistribution study after
8 days p.i. A mean activity of 19.0 ± 2.5 MBq/kg was
injected. Animals were sacrificed after 5 min, 60 min,
and 8 days p.i. Organs of interest were excised rapidly
and weighed, and the 177Lu activity was determined
with a Wallac WIZARD automatic gamma counter
(PerkinElmer, Germany) and decay corrected. The
distribution data are expressed in %ID or are normal-
ized to the BW as standard uptake value (SUV),
which was calculated with the formula: SUV = (activity
per g tissue)/(injected activity) × BW. The skeleton
weight was calculated using the following: skeleton
weight = 9.66 + 0.0355 × BW, and the total activities
associated with the skeleton were calculated by using
the activity concentration in the femur and the total
skeleton weight [29].
Metabolite analysis and in vivo stability
Arterial blood plasma samples were taken during SPECT/
CT examinations after 1, 3, 5, 10, 20, 30, 60, and 120 min.
p.i., and the in vivo metabolism of [177Lu]BPAMD,
[177Lu]BPAPD, [177Lu]BPPED, [177Lu]NO2APBP, [177Lu]DO-
TA(MBP)2, and [
177Lu]DO2A(PBP)2 was analyzed.
Plasma was separated by centrifugation (3 min,
11,000×g) followed by precipitation of the plasma
proteins with ice-cold methanol (1.5 parts per 1
part plasma) and centrifugation (3 min, 11,000×g).
The supernatants were analyzed by radio-TLC and
HPLC using the abovementioned methods for qual-
ity control. Additionally, urine samples were treated
in the same way prior radio-TLC and radio-HPLC
analysis.Scheme 2 Synthesis of DO2A(PBP)2. (i) Toluene, H2CO, reflux (ii) 6 M HClSPECT/CT
Tracer accumulation in vivo was monitored with a
NanoScan® SPECT (Mediso Medical Imaging Systems,
Budapest, Hungary) scanner. CT images were obtained
with a NanoScan® PET/CT (Mediso Medical Imaging,
Budapest Hungary) scanner. Rats were prone and
head-first positioned. The animals were anesthetized
by 5 % desflurane inhalation.
Statistical analysis
The statistical analysis was performed by using GraphPad
Prism (V5.02 for Windows, GraphPad Software, San
Diego California USA, www.graphpad.com). Data are
expressed as an average ± standard deviation (S.D.). Two-
tailed Student’s t test or ANOVA was usually done to
compare groups of data.
Results
Synthesis
The pendant arms (1) and (4) were prepared as described
in literature procedures (see experimental part) in good
yields. Alkylation of DO2A was done by a nucleophilic
substitution (2) or by a mannich-like reaction (5), followed
by a two-step cleavage (3) of the protection groups, by
using trimethylsilyl bromide as a mild and efficient de-
esterification agent of ethyl-protected bisphosphonates and
trifluoroacetic acid for the tert.-butylesters of the carboxylic
acid arms. Aqueous HCl (6 M) was used to de-protect the
phosphinate compound (6) (Schemes 1 and 2). The
final dimeric bisphosphonates DOTA(MBP)2 (3) and
DO2A(PBP)2 (6) were obtained in moderate yields
after resin and recrystallization purification.
Radiolabelling with n.c.a. 177Lu and quality control
The DOTA-, DO2A-, and NO2A-conjugated bisphospho-
nates were successfully labelled with n.c.a. 177Lu(III).
Yields and purities were controlled by radio-TLC and
HPLC (Fig. 1) All bisphosphonates showed a very fast
Fig. 1 Radio-HPLC chromatograms of [177Lu]BPAMD, [177Lu]BPAPD, and [177Lu]NO2APBP as a representative for 177Lu-labelled bisphosphonates in
comparison to 177Lu3+
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cellent complexation ability with lanthanides, a radiochem-
ical yield (RCY) of more than 98 % was obtained for the
abovementioned compounds within 30 min. Even the
NO2A-based bisphosphonate NO2APBP showed an
excellent labelling efficiency. Complexation occurred fast
and quantitative (RCY > 99 %).Table 1 Biodistribution of radioactivity after 5 min p.i. of 177Lu-comp
Organ [177Lu]citrate [177Lu]BPAMD [177Lu]BPAPD [177Lu
Mean SD Mean SD Mean SD Mean
Blood n.d. n.d. 0.90 0.42 0.84 0.07 1.30
Brain n.d. n.d. 0.04 0.01 0.05 0.02 0.04
Pancreas n.d. n.d. 0.31 0.14 1.60 1.18 0.37
Spleen n.d. n.d. 0.37 0.35 1.27 0.94 0.39
Adrenal gland n.d. n.d. 0.40 0.13 0.55 0.17 0.70
Kidneys n.d. n.d. 4.53 4.01 3.61 1.81 3.09
Adipose tissue n.d. n.d. 0.42 0.19 1.80 0.78 0.24
Muscle n.d. n.d. 0.19 0.08 0.78 0.70 0.24
Heart n.d. n.d. 0.36 0.14 0.36 0.04 0.52
Lung n.d. n.d. 0.61 0.24 0.61 0.07 0.75
Thymus n.d. n.d. 0.29 0.11 0.30 0.06 0.38
Harderian gland n.d. n.d. 0.36 0.13 0.37 0.10 0.40
Liver n.d. n.d. 0.26 0.11 0.39 0.08 0.48
Testes n.d. n.d. 0.25 0.07 0.28 0.03 0.36
Femur n.d. n.d. 3.36 0.63 3.43 0.44 4.16
Data are expressed in SUV. Each value represents the mean (S.D.) of four animals
n.d. data not determinedBiodistribution
The 177Lu-labelled bisphosphonates showed a similar
organ distribution with a predominant accumulation in
the skeleton, cf. Tables 1, 2, and 3. Besides the bone, an
appreciable amount of activity was found in the kidneys,
which is reasonable according to the compound’s renal
clearance. Considerable liver accumulation was onlylexes in Wistar rats
]BPPED [177Lu]NO2APBP [177Lu]DO2A(PBP)2 [
177Lu]DOTA(MBP)2
SD Mean SD Mean SD Mean SD
0.20 2.08 2.83 3.35 0.33 3.98 0.40
0.01 0.04 0.01 0.09 0.01 0.13 0.03
0.12 0.27 0.08 0.73 0.15 0.68 0.14
0.05 0.23 0.03 0.60 0.13 0.78 0.10
0.41 0.60 0.42 1.23 0.19 1.07 0.19
0.48 3.08 1.14 2.87 0.29 3.10 0.54
0.07 0.53 0.14 1.52 0.50 0.55 0.13
0.03 0.21 0.05 0.49 0.30 0.49 0.11
0.10 0.31 0.06 1.34 0.17 1.45 0.30
0.08 0.50 0.05 1.87 0.41 2.04 0.32
0.08 0.22 0.04 0.76 0.09 0.93 0.14
0.12 0.35 0.08 0.95 0.23 1.12 0.16
0.12 0.29 0.12 1.07 0.15 1.13 0.39
0.01 0.32 0.05 0.24 0.02 0.30 0.03
0.35 2.67 0.04 2.11 0.22 2.31 0.15
Table 2 Biodistribution of radioactivity after 60 min p.i. of 177Lu-complexes in Wistar rats
Organ [177Lu]citrate [177Lu]BPAMD [177Lu]BPAPD [177Lu]BPPED [177Lu]NO2APBP [177Lu]DO2A(PBP)2 [
177Lu]DOTA(MBP)2
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Blood 0.22 0.11 0.04 0.01 0.04 0.00 0.06 0.01 0.07 0.02 1.25 0.09 1.43 0.32
Brain 0.06 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.04 0.01 0.05 0.01
Pancreas 0.50 0.05 0.04 0.02 0.04 0.02 0.03 0.01 0.06 0.01 0.31 0.05 0.30 0.07
Spleen 0.70 0.12 0.07 0.06 0.05 0.01 0.14 0.04 0.05 0.01 0.31 0.03 0.52 0.25
Adrenal gland 0.62 0.05 0.04 0.04 0.09 0.06 0.08 0.12 0.11 0.05 0.49 0.09 0.52 0.20
Kidneys 1.41 0.11 0.35 0.06 0.39 0.06 0.38 0.04 0.47 0.07 1.66 0.40 1.41 0.16
Adipose tissue 0.35 0.03 0.04 0.02 0.06 0.02 0.02 0.01 0.09 0.03 0.55 0.12 0.29 0.16
Muscle 0.35 0.02 0.02 0.01 0.03 0.02 0.02 0.00 0.02 0.01 0.15 0.01 0.24 0.06
Heart 0.87 0.10 0.02 0.01 0.03 0.00 0.04 0.01 0.04 0.01 0.54 0.10 0.63 0.12
Lung 1.13 0.13 0.07 0.01 0.06 0.00 0.08 0.02 0.07 0.01 0.89 0.12 0.89 0.13
Thymus 0.53 0.09 0.08 0.04 0.06 0.02 0.03 0.01 0.06 0.01 0.39 0.05 0.37 0.10
Harderian gland 9.62 5.62 0.04 0.01 0.11 0.11 0.16 0.08 0.06 0.01 0.42 0.05 0.46 0.09
Liver 1.04 0.09 0.04 0.01 0.04 0.01 0.13 0.01 0.04 0.00 0.52 0.11 0.69 0.36
Testes 0.42 0.03 0.03 0.01 0.02 0.01 0.03 0.00 0.03 0.01 0.28 0.03 0.33 0.04
Femur 4.12 0.31 4.84 0.44 4.05 0.36 5.67 0.10 3.34 0.28 4.48 0.38 5.41 0.46
Data are expressed in SUV. Each value represents the mean (S.D.) of four animals
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in the blood, liver, and kidney showed the strongest varia-
tions between the tested compounds. The highest blood
levels were determined for the dimeric compound
[177Lu]DOTA(MBP)2. The lowest blood SUV was obtained
for [177Lu]BPAMD. Activity accumulation in the kidneys
was lowest for [177Lu]BPAMD and [177Lu]BPAPD. Highest
kidney concentrations were found for the dimericTable 3 Biodistribution of radioactivity after 8 days p.i. of 177Lu-com
Organ [177Lu]citrate [177Lu]BPAMD [177Lu]BPAPD [177Lu
Mean SD Mean SD Mean SD Mean
Blood n.d. n.d. 0.001 0.000 n.d. n.d. 0.001
Brain n.d. n.d. 0.004 0.001 n.d. n.d. 0.014
Pancreas n.d. n.d. 0.006 0.001 n.d. n.d. 0.005
Spleen n.d. n.d. 0.020 0.002 n.d. n.d. 0.021
Adrenal gland n.d. n.d. 0.009 0.006 n.d. n.d. 0.033
Kidneys n.d. n.d. 0.076 0.015 n.d. n.d. 0.088
Adipose tissue n.d. n.d. 0.004 0.003 n.d. n.d. 0.004
Muscle n.d. n.d. 0.136 0.107 n.d. n.d. 0.027
Heart n.d. n.d. 0.006 0.001 n.d. n.d. 0.008
Lung n.d. n.d. 0.008 0.001 n.d. n.d. 0.008
Thymus n.d. n.d. 0.006 0.001 n.d. n.d. 0.006
Harderian gland n.d. n.d. 0.105 0.127 n.d. n.d. 0.113
Liver n.d. n.d. 0.025 0.002 n.d. n.d. 0.027
Testes n.d. n.d. 0.004 0.000 n.d. n.d. 0.004
Femur n.d. n.d. 5.039 0.453 n.d. n.d. 5.197
Data are expressed in SUV. Each value represents the mean (S.D.) for five animals. As a
n.d. data not determinedbisphosphonates [177Lu]DO2A(PBP)2 and [
177Lu]DO-
TA(MBP)2 as well as for [
177Lu]citrate. The highest SUV
determined for [177Lu]citrate was found in the harderian
glands with a value of 9.62 ± 5.62, which is more than the
doubled uptake value compared to the femur after 60 min
p.i. in contrast to the tested bisphosphonates, which
showed almost no uptake in the harderian glands. The
data showing that the bone accumulation isplexes in Wistar rats
]BPPED [177Lu]NO2APBP [177Lu]DO2A(PBP)2 [
177Lu]DOTA(MBP)2
SD Mean SD Mean SD Mean SD
0.001 n.d. n.d. n.d. n.d. 0.003 0.001
0.021 n.d. n.d. n.d. n.d. 0.018 0.007
0.003 n.d. n.d. n.d. n.d. 0.067 0.019
0.003 n.d. n.d. n.d. n.d. 0.697 0.348
0.011 n.d. n.d. n.d. n.d. 0.166 0.063
0.010 n.d. n.d. n.d. n.d. 0.369 0.075
0.004 n.d. n.d. n.d. n.d. 0.026 0.012
0.056 n.d. n.d. n.d. n.d. 0.024 0.003
0.001 n.d. n.d. n.d. n.d. 0.099 0.024
0.002 n.d. n.d. n.d. n.d. 0.117 0.045
0.002 n.d. n.d. n.d. n.d. 0.109 0.033
0.132 n.d. n.d. n.d. n.d. 0.331 0.131
0.003 n.d. n.d. n.d. n.d. 0.470 0.078
0.001 n.d. n.d. n.d. n.d. 0.050 0.005
0.435 n.d. n.d. n.d. n.d. 7.340 1.009
n exception are the data in three decimal places to show also the very low values
Fig. 2 Accumulation of 177Lu-labelled compounds a 60 min and b 8 days p.i. in the femur. Values are mean ± SD (SUV) of the activity concentrations
in both femurs of a four and b five healthy Wistar rats. In a, the accumulation in the femur was compared between [177Lu]citrate and the other
radiotracers and in b between [177Lu]DOTA(MBP)2 and the other radiotracers. The P values are *<0.05; **<0.01, and ****<0.0001
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ure 2 summerizes the bone accumulation of the in-
vestigated complexes. Figure 3 represents the activity
concentration in the blood over time.
The “bone to soft tissue” ratios are presented in Tables 4,
5, and 6. The best bone-to-muscle ratio was observed for
[177Lu]BPPED (355.8). [177Lu]BPPED showed as well the
best bone-to-kidney ratio. The best bone-to-liver ratio was
determined for [177Lu]BPAMD (127.5), while the lowest
ratio was obtained for [177Lu]citrate (4.0). The total skeleton
retention was calculated as the following: starting with the
lowest value of 30.5 ± 1.1 %ID for [177Lu]NO2APBP, 39.4 ±
2.5 %ID for [177Lu]BPAPD, 44.6 ± 3.2 %ID for
[177Lu]DO2A(PBP)2, 45.7 ± 6.2 %ID for [
177Lu]citrate, 46.7 ±
5.3 %ID for [177Lu]BPAMD, 48.2 ± 4.1 %ID for [177Lu]DO-
TA(MBP)2, and 56.3 ± 6.7 %ID for [
177Lu]BPPED after











Fig. 3 Time activity concentration curves of [177Lu]BPAMD, [177Lu]BPAPD, [1
in arterial blood of Wistar rats after single intravenous injection, respectivel8 days for [177Lu]BPAMD and [177Lu]BPPED. Only the total
skeletal retention of [177Lu]DOTA(MBP)2 increased to 64.5
± 1.5 %ID but showed at the same time the minimal target
to soft-tissue ratio.Metabolite analysis and in vivo stability
Radio-HPLC and TLC analysis of blood samples showed
no evidence of any metabolization of the compounds
[177Lu]NO2APBP, [177Lu]BPAMD, [177Lu]BPAPD, and
[177Lu]BPPED within a period of 120 min. The abovemen-
tioned compounds were found to be intact in the urine
and the serum probes, and no traces of unknown
177Lu species or compounds were observed. The blood
half-lives of the slow components (t1/2(β)) were
23.3 min for [177Lu]BPAMD, 10.4 min for [177Lu]BPAPD,







77Lu]BPPED, [177Lu]NO2APBP, [177Lu]DO2A(PBP)2, and [
177Lu]DOTA(MBP)2
y
Table 4 Ratios between bone and soft tissue after 5 min p.i. of 177Lu-complexes in Wistar rats
Bone/organ [177Lu]citrate [177Lu]BPAMD [177Lu]BPAPD [177Lu]BPPED [177Lu]NO2APBP [177Lu]DO2A(PBP)2 [
177Lu]DOTA(MBP)2
Blood n.d. 3.7 4.1 3.2 1.3 0.6 0.6
Brain n.d. 83.9 68.5 104.0 66.8 23.4 17.7
Pancreas n.d. 10.8 2.1 11.2 9.9 2.9 3.4
Spleen n.d. 9.1 2.7 10.7 11.6 3.5 3.0
Adrenal gland n.d. 8.4 6.2 5.9 4.5 1.7 2.2
Kidneys n.d. 0.7 0.9 1.3 0.9 0.7 0.7
Adipose tissue n.d. 8.0 1.9 17.3 5.0 1.4 4.2
Muscle n.d. 17.7 4.4 17.3 12.7 4.3 4.7
Heart n.d. 9.3 9.5 8.0 8.6 1.6 1.6
Lung n.d. 5.5 5.6 5.5 5.3 1.1 1.1
Thymus n.d. 11.6 11.4 10.9 12.1 2.8 2.5
Harderian gland n.d. 9.3 9.3 10.4 7.6 2.2 2.1
Liver n.d. 12.9 8.8 8.7 9.2 2.0 2.0
Testes n.d. 13.4 12.2 11.6 8.3 8.8 7.7
n.d. data not determined
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[177Lu]DOTA(MBP)2.SPECT/CT molecular imaging in vivo
Images obtained from SPECT showed that the the-
rapeutic 177Lu-labelled bisphosphonates exclusively
accumulated in the skeleton with a high target-to-
background ratio, cf. Figs. 4 and 5. No considerable
fractions of 177Lu activity were found in other organs
after 60 min, which is consistent to the data gath-
ered from the ex vivo biodistribution. An obvious
amount of activity was present in the growth plate
as well as in other articulations.Table 5 Ratios between bone and soft tissue after 60 min p.i. of 177
Bone/organ [177Lu]citrate [177Lu]BPAMD [177Lu]BPAPD [177L
Blood 18.7 135.6 95.1 92.9
Brain 65.4 613.4 513.9 419
Pancreas 8.2 136.4 104.9 181
Spleen 5.8 68.2 85.7 41.0
Adrenal gland 6.6 109.6 45.8 72.5
Kidneys 2.9 14.0 10.3 14.9
Adipose tissue 11.8 134.5 70.7 269
Muscle 11.8 251.7 158.7 355
Heart 4.7 210.1 158.7 141
Lung 3.7 69.1 62.6 67.5
Thymus 7.7 58.6 70.7 212
Harderian gland 0.4 118.8 35.8 36.4
Liver 4.0 127.5 105.4 42.3
Testes 9.9 179.1 199.7 185Discussion
The DOTA-based monomeric bisphosphonates BPAMD,
BPAPD, and BPPED have been successfully radiolabeled
with the therapeutic β−-emitter 177Lu(III) in excellent
yields over 98 % as well as the NO2A-based bispho-
sphonate NO2APBP and the dimeric compounds
DOTA(MBP)2 and DO2A(P
BP)2. All tracers tested
showed a distinguished high accumulation on the bone
surface, eminently in the epiphyseal plate. We suppose
that this particular uptake in the epiphyseal areas may
serve as an analogy to the tracer’s behavior on bone
metastases. High uptakes were observed for the dimeric
compound [177Lu]DOTA(MBP)2 (SUVfemur = 5.41 ± 0.41).
All bisphosphonates underwent a renal body clearance,Lu-complexes in Wistar rats
u]BPPED [177Lu]NO2APBP [177Lu]DO2A(PBP)2 [
177Lu]DOTA(MBP)2
45.8 3.6 3.8
.9 254.3 111.5 104.0




.7 37.2 8.2 18.4
.8 141.4 29.8 22.9
.1 89.0 8.2 8.6
46.8 5.1 6.1
.0 59.0 11.6 14.4
85.6 10.6 11.7
87.0 8.6 7.8
.1 113.5 15.8 16.2
Table 6 Ratios between bone and soft tissue after 8 days p.i. of 177Lu-complexes in Wistar rats
Bone/organ [177Lu]citrate [177Lu]BPAMD [177Lu]BPAPD [177Lu]BPPED [177Lu]NO2APBP [177Lu]DO2A(PBP)2 [
177Lu]DOTA(MBP)2
Blood n.d. 6703 n.d. 5123 n.d. n.d. 2639
Brain n.d. 1405 n.d. 365 n.d. n.d. 419
Pancreas n.d. 851 n.d. 1104 n.d. n.d. 110
Spleen n.d. 257 n.d. 246 n.d. n.d. 11
Adrenal gland n.d. 547 n.d. 159 n.d. n.d. 44
Kidneys n.d. 66 n.d. 59 n.d. n.d. 20
Adipose tissue n.d. 1158 n.d. 1231 n.d. n.d. 287
Muscle n.d. 37 n.d. 192 n.d. n.d. 312
Heart n.d. 885 n.d. 653 n.d. n.d. 74
Lung n.d. 634 n.d. 637 n.d. n.d. 63
Thymus n.d. 787 n.d. 933 n.d. n.d. 67
Harderian gland n.d. 48 n.d. 46 n.d. n.d. 22
Liver n.d. 203 n.d. 189 n.d. n.d. 16
Testes n.d. 1136 n.d. 1214 n.d. n.d. 148
n.d. data not determined
Fig. 4 MIP of [177Lu]citrate, [177Lu]BPAMD, [177Lu]BPAPD, [177Lu]BPPED,
[177Lu]NO2APBP, [177Lu]DO2A(PBP)2, and [
177Lu]DOTA(MBP)2 in Wistar
rats after 1 h of single intravenous injection, respectively
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monomeric compounds. No brain or notable liver uptake
was observed. The compounds were found to be complete
intact in the urine and blood.
The characteristic accumulation specific in the growth
plate of the skeleton shows that the compound uptake
profile is subject to the bone turnover. For that reason,
the described compounds in this manuscript should be
well suited for a targeted 177Lu therapy to osteoblastic
bone metastases, where they should preferably accumu-
late. An important factor for a therapeutic application is
the target-to-background ratio (TBR) and a fast excretion
of non-target bond activity. A good TBR and a fast blood
and body clearance reduces the radiation dose of the non-
targeted tissue and thus will reduce toxic side effects and
enhances the therapeutic efficiency and tolerance.
Although the dimeric compounds [177Lu]DOTA(MBP)2
and [177Lu]DO2A(PBP)2 showed the highest bone accu-
mulation, their TBR was lowest, besides [177Lu]citrate.
The additional bisphosphonate moiety may have a
stronger bone-binding effect, albeit the blood levels of
these compounds were significantly higher after
60 min (SUVblood{[
177Lu]DOTA(MBP)2} = 1.43 ± 0.32;
SUVblood{[
177Lu]DO2A(PBP)2} = 1.25 ± 0.09) compared to
the monomeric bisphosphonates (SUVblood{[
177Lu]BP
AMD} = 0.04 ± 0.01; SUVblood{[
177Lu]NO2APBP} = 0.07 ±
0.02). It might be the case that these higher blood concen-
trations are the reason for the enhanced skeletal accumula-
tion. Because of the fast blood and renal clearance of the
monomeric bisphosphonates, the time scale for target
accumulation is shortened compared to the dimeric
compounds. The reason for the decreased clearance of the
dimers is yet not clear and it might be an effect of the
higher negative charge of these compounds or may beinfluenced by serum protein binding. The data from
ex vivo organ distribution of the dimeric bisphosphonates
are also not matching with [177Lu]citrate. Liver uptake,
Fig. 5 MIP of [177Lu]BPAMD, [177Lu]BPPED, and [177Lu]DOTA(MBP)2 in Wistar rats after 8 days of single intravenous injection, respectively
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as well as in the femur are significantly different. If a
therapeutic approach of bone metastases benefits
from the higher skeleton accumulation of the dimeric
bisphosphonates, it has yet to be evaluated in future
in a dosimetry study, considering the lower TBR and
the higher blood levels.
The lowest skeleton uptake was observed for the NO-
2A phosphinate-linked bisphosphonate [177Lu]NO2APBP
(SUVfemur{[
177Lu]NO2APBP} = 3.34 ± 0.28, 60 min p.i.).
Contrary to the results with 177Lu(III), it was reported pre-
viously that [68Ga]NO2APBP showed an excellent bone
binding with a brilliant TBR [22], remarkably suitable as a
PET imaging agent. However, it is known that lan-
thanides require seven-dentate chelators like DOTA
derivates, and the NO2A phosphinate offers only six.
Since the bisphosphonate moiety is able to complex diva-
lent metal ions like Ca2+, it might be the case that some
parts of the phosphonate groups function as additional
donors to the 177Lu-NO2AP complex. A partial loss of the
functional bisphosphonate moiety due to stabilizing the
177Lu(III) complex might reduce the binding potential of
the bisphosphonate group to the bone and thus reduces
the affinity of the [177Lu]NO2APBP compound to the tar-
get tissue in contrast to the 68Ga(III) complex.
Highest bone accumulation of tested tracers was
observed for [177Lu]BPPED with a SUV of 5.67 ± 0.10 in
the femur after 60 min and [177Lu]DOTA(MBP)2 after
8 days. [177Lu]BPPED showed a TBR of the muscle and
blood of 355.8 and 92.3, respectively. Excellent boneaccumulation (SUV = 4.84 ± 0.44) as well as a superior
TBRs were observed also for [177Lu]BPAMD, with TBR
values of 127.5 to the liver and 135.6 to the blood, which
was the highest for all tested compounds. [177Lu]B-
PAMD revealed a very fast blood clearance and renal
excretion.
Conclusions
Within this study, BPAMD showed to be a potential
bone-targeting agent to treat skeletal metastases with
177Lu. Contrary to other actual discussed tracers like
EDTMP, BPAMD proved to be an efficient 68Ga-PET
imaging agent for bone metastasis [21]. Neither [177Lu/
153Sm]Lu/Sm-EDTMP nor [223Ra]RaCl2 offer this thera-
nostic approach. Patients may benefit from a specific
[177Lu]BPAMD dose application, calculated from the pa-
tients’ individual uptake profile previously (pre-thera-
peutically) determined by [68Ga]BPAMD PET
examinations. The same way, post-therapeutic quanti-
tative PET studies are possible.
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